Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that on December 19, its U.K. subsidiary, Eisai Ltd. (Headquarters: London, President: Paul Hooper), submitted a Marketing Authorization Application (MAA) for a rapid disintegration tablet formulation of ARICEPT to the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA will act as the Reference Member State for the European Union's (EU) Mutual Recognition procedure.
The new form of ARICEPT is designed to make administration easier for patients who have difficulty swallowing tablets and will contribute to improved compliance for more patients suffering from Alzheimer's disease. Eisai submitted a New Drug Application (NDA) for a rapid disintegration tablet in Japan in March 2003 and in the U.S. in December 2003.
ARICEPT , an acetylcholinesterase inhibitor developed by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter in the brain. ARICEPT is currently indicated for the treatment of mild to moderate Alzheimer's disease and is marketed in 62 countries worldwide. Eisai markets ARICEPT through copromotion with Pfizer in Japan, the United States, the United Kingdom, Germany, France and Spain, and markets solely in Asian countries.
Eisai Co., Ltd.
Public Relations Department
Phone 03-3817-5120 (Tokyo)